Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glaxo SmithKline

- PMLiVE

Revlimid faces NICE rejection for use in rare blood cancer

Watchdog's draft guidance does not recommend Celgene's drug for NHS use in England and Wales

Novartis sponsors rare disease patient community

Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)

- PMLiVE

The marketer’s role in early drug development

Why as a marketer you can do much to enable your R&D colleagues to find a product’s added value

- PMLiVE

GSK signs $500m-plus technology deal with Immunocore

Will make use of ImmTAC technology to activate immune system to kill cancerous or infected cells

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

- PMLiVE

GSK’s Botox sales in China under scrutiny says WSJ

Newspaper says it has reviewed company documents that discuss giving kickbacks to doctors to prescribe Botox

- PMLiVE

Novartis enters developing nations vaccines partnership

Will work with Biological E to deliver vaccines for typhoid and paratyphoid A fevers

- PMLiVE

Allergan’s Julia Kendrick recognised as Young Achiever

Stood out in a hotly contested category at the Communiqué Awards 2013

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis study

Phase III results show the antibody is more effective than Amgen/Pfizer's blockbuster

Novartis day

Lucentis cleared in Europe for pathological myopia

Makes Novartis' drug the first anti-VEGF approved in this setting

- PMLiVE

GSK’s Philip Thomson named Communiquetor of the Year

Recognised for stewardship of pharma company's global communications team

- PMLiVE

Pharma facing EU challenge over promotional products ban

Manufacturers of USB sticks, sticky notes and pens complain to the European Commission

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links